For adults struggling with weight, a weekly injection of tirzepatide offers real hope. Recent findings presented at the ...

Tirzepatide was approved in November 2023 by the US Food and Drug Administration (FDA) (Zepbound) and in the EU in June 2024 ...

But which medication is right for you? Tirzepatide is the active ingredient in Zepbound, approved by the Food and Drug Administration (FDA) specifically for weight loss. Semaglutide was initially ...

Now, there may be another option for him. It's a drug called tirzepatide, also known as Mounjaro or Zepbound. It's FDA approved to manage diabetes and obesity. Now, UC San Diego researchers have ...

Researchers at Mass General Brigham found that by December 2023, over one-third of all new prescriptions for type 2 diabetes were for GLP-1 receptor agonists, such as semaglutide or tirzepatide. New ...

Tirzepatide is approved for 3 indications in the US: type 2 diabetes, chronic weight management, and obstructive sleep apnea.

The drug tirzepatide improved kidney function and cardiovascular outcomes among patients with obesity and heart failure with preserved ejection fraction (HFpEF) compared with placebo at one year, ...

For adults struggling with weight, a weekly injection of tirzepatide offers real hope. Recent findings presented at the European Congress on Obesity (ECO) in Malaga, Spain, reveal that the drug ...

Each participant received weekly doses of tirzepatide—either 5 mg, 10 mg, or 15 mg—for three years. At the end of this period, the results were impressive. On average, participants lost ...